Showing 14 posts of 14 posts found.

Eli Lilly shares positive analysis from phase 3 trial for lebrikizumab for atopic dermatitis

May 3, 2023
Research and Development Dermatology, Eli Lilly, Jenny Murase, atopic dermatitis, dermatology, lebrikizumab

Eli Lilly has announced new secondary analysis from its phase 3 clinical development programme for patients with atopic dermatitis (AD) …


Global orphan and rare dermatology market set to exceed $6 billion by 2024

August 31, 2018
Medical Communications Orphan Drugs, analysis, dermatology, market reports, rare diseases

The global orphan and rare dermatology premium products market is expected to grow rapidly in the next half a decade …


Almirall picks up Allergan’s dermatology portfolio to for $650m

August 3, 2018
Medical Communications, Sales and Marketing Allergan, Almirall, dermatology, pharma

Allergan has sealed a deal to sell its dermatology portfolio, comprising five brands, to Spanish pharmaceutical firm Almirall for $650 …

Artificial skin development has implications for clinical trials

January 23, 2017
Medical Communications, Sales and Marketing Seoul National University Hospital, artificial skin, dermatology

Researchers from Seoul National University Hospital have announced that it has developed a microchip that has been designed to replicate …

Almirall logo

Almirall to acquire Poli Group’s skin drugs

November 30, 2015
Sales and Marketing Almirall, Poldi, dermatology, skin, specialty pharma

Almirall has agreed to acquire 100% of the share capital of Poli Group Holding as the Spanish pharma company continues …

LEO logo

LEO Pharma buys dermatology portfolio from Astellas

November 12, 2015
Sales and Marketing Astellas, LEO Pharma, acquisitions, dermatology, mergers

LEO Pharma, the speciality dermatology firm, is looking to expand its presence in the therapy area by buying Astellas’ portfolio …

Novartis emphasises pharma growth

June 19, 2014
Sales and Marketing Novartis, breezhaler, dermatology, heart failure, oncology, respiratory

Novartis is to grow its pharma business by focussing on five key areas and predicts that it will have 14 …

Novartis image

Novartis to acquire Fougera for $1.5 billion

May 3, 2012
Sales and Marketing Fougera, Novartis, dermatology, generics, gilenya

Novartis will acquire the dermatology generics firm Fougera for $1.53 billion in cash.  Novartis’ generic unit Sandoz is conducting the …

Abbott launches ‘Outside In’ initiative for psoriatic arthritis

March 21, 2012
Medical Communications, Sales and Marketing Abbott, Outside In, dermatology, med ed, psoriatic arthritis

An expert group of rheumatologists and dermatologists have come together with Abbott to develop new clinical tools for psoriatic arthritis …

Sanofi spots acne vaccine opportunity

September 22, 2011
Research and Development Sanofi, acne, dermatology

Sanofi Pasteur has signed a new research deal with the University of California, San Diego for its investigational acne vaccine. …


Sanofi sells dermatology unit for $425m

July 11, 2011
Manufacturing and Production, Sales and Marketing Canada, Dermik, Sanofi, Valeant, dermatology

Sanofi has sold its Canadian dermatology unit Dermik for $425 million in order to concentrate on key growth areas like …


AZ partners with Galderma on psoriasis research

March 9, 2011
Research and Development AZ, AstraZeneca, Galderma, dermatology, psoriasis

AstraZeneca has signed a five-year deal with dermatology specialist Galderma Pharma to develop new treatments for conditions including psoriasis. It …

Latest content